The impact of hospital type on the efficacy of chemotherapy treatment in ovarian cancer patients.

[1]  J. Coebergh,et al.  Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. , 2009, Gynecologic oncology.

[2]  J. Coebergh,et al.  Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study. , 2008, Journal of the National Cancer Institute.

[3]  L. Savage,et al.  Anthracyclines Improve Survival in HER2-Positive Breast Cancer Patients , 2008 .

[4]  J. Thigpen.  Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy , 2008 .

[5]  M. Carey,et al.  The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. , 2008, Gynecologic oncology.

[6]  Y. van der Graaf,et al.  The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. , 2007, Gynecologic oncology.

[7]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[8]  C. Earle,et al.  Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. , 2006, Journal of the National Cancer Institute.

[9]  S. Tretli,et al.  Improved short‐term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[10]  E. D. de Vries,et al.  Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma , 2006, Cancer.

[11]  M. Janssen-Heijnen,et al.  The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. , 2005, Gynecologic oncology.

[12]  D G Altman,et al.  Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines , 2004, British Journal of Cancer.

[13]  B. Hagen,et al.  THE EFFECT OF CENTRALIZATION OF PRIMARY SURGERY ON SURVIVAL IN OVARIAN CANCER PATIENTS , 2003, International Journal of Gynecologic Cancer.

[14]  V. Torri,et al.  Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. , 2003, Lancet.

[15]  H. Hansen,et al.  Performance status rather than age is the key prognostic factor in second‐line treatment of elderly patients with epithelial ovarian carcinoma , 2002, Cancer.

[16]  D. Hole,et al.  Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients , 1999, British journal of obstetrics and gynaecology.

[17]  K. Tilling,et al.  Management and survival of ovarian cancer patients in south east England. , 1997, European journal of cancer.

[18]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.